These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cell Death and microRNAs in Cholestatic Liver Diseases: Update on Potential Therapeutic Applications. Castro RE; Rodrigues CMP Curr Drug Targets; 2017; 18(8):921-931. PubMed ID: 26477457 [TBL] [Abstract][Full Text] [Related]
3. Cholestatic liver diseases: slow progress in understanding and treating slowly progressive disorders. Vleggaar FP; Van Ooteghem NA; Van Buuren HR; Van Berge Henegouwen GP Scand J Gastroenterol Suppl; 2000; (232):86-92. PubMed ID: 11232499 [TBL] [Abstract][Full Text] [Related]
4. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease. Lirussi F; Okolicsanyi L Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577 [TBL] [Abstract][Full Text] [Related]
5. Bile salts and cholestasis. Maillette de Buy Wenniger L; Beuers U Dig Liver Dis; 2010 Jun; 42(6):409-18. PubMed ID: 20434968 [TBL] [Abstract][Full Text] [Related]
6. [Bile formation and cholestasis]. Jansen PL; Müller M; Kuipers F Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2384-91. PubMed ID: 11145092 [TBL] [Abstract][Full Text] [Related]
7. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Li Y; Tang R; Leung PSC; Gershwin ME; Ma X Autoimmun Rev; 2017 Sep; 16(9):885-896. PubMed ID: 28698093 [TBL] [Abstract][Full Text] [Related]
8. The pathophysiology of cholestasis with special reference to primary biliary cirrhosis. Jansen PL Baillieres Best Pract Res Clin Gastroenterol; 2000 Aug; 14(4):571-83. PubMed ID: 10976015 [TBL] [Abstract][Full Text] [Related]
9. Genetics of cholestatic liver disease in 2010. Karlsen TH; Hov JR Curr Opin Gastroenterol; 2010 May; 26(3):251-8. PubMed ID: 20042859 [TBL] [Abstract][Full Text] [Related]
10. Genetic variations of bile salt transporters as predisposing factors for drug-induced cholestasis, intrahepatic cholestasis of pregnancy and therapeutic response of viral hepatitis. Stieger B; Geier A Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):411-25. PubMed ID: 21320040 [TBL] [Abstract][Full Text] [Related]
11. [Cholestasis and cholestatic liver diseases]. Poupon R Gastroenterol Clin Biol; 2009; 33(8-9):778-88. PubMed ID: 19556086 [TBL] [Abstract][Full Text] [Related]
12. Primary biliary cholangitis: A tale of epigenetically-induced secretory failure? Rodrigues PM; Perugorria MJ; Santos-Laso A; Bujanda L; Beuers U; Banales JM J Hepatol; 2018 Dec; 69(6):1371-1383. PubMed ID: 30193962 [TBL] [Abstract][Full Text] [Related]
15. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Zollner G; Wagner M; Fickert P; Silbert D; Gumhold J; Zatloukal K; Denk H; Trauner M Liver Int; 2007 Sep; 27(7):920-9. PubMed ID: 17696930 [TBL] [Abstract][Full Text] [Related]
17. Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases. Yang T; Khan GJ; Wu Z; Wang X; Zhang L; Jiang Z Drug Discov Today; 2019 Jan; 24(1):112-128. PubMed ID: 30244079 [TBL] [Abstract][Full Text] [Related]
18. [Molecular mechanisms of bile formation and cholestatic diseases]. Poupon R Bull Acad Natl Med; 2003; 187(7):1261-74; discussion 1274-6. PubMed ID: 15146603 [TBL] [Abstract][Full Text] [Related]
19. [Value of determining bile acids in the blood of patients with chronic cholestatic hepatitis and primary biliary cirrhosis]. Radchenko VG; Mekhanik ZI Vrach Delo; 1985 May; (5):26-8. PubMed ID: 4013219 [No Abstract] [Full Text] [Related]